QBE shrugs off dour market conditions to grow its FY22 net profit by $20m
QBE (ASX:QBE) managed to grow its FY22 NPAT by $20m in spite of difficult market conditions. It isn’t an easy time to be an insurer, but the company’s premium growth was enough to counter the market.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
QBE records a solid result
QBE’s FY22 NPAT was US$770m, up from US$750m in FY21, and it recorded a 10.5% cash Return on Equity.
The company paid a total dividend of 3c per share, representing a payout ratio of 48% of adjusted cash profit and a 2.9% yield at yesterday’s closing share price.
QBE (ASX:QBE) 1-year share price chart, log scale (Source: TradingView)
Premiums make up for difficult conditions
There were difficult economic conditions during 2022 with heightened inflation, geopolitical tensions, elevated catastrophic activity and poor financial market conditions.
Indeed, QBE recorded an investment loss of $776m after a $122m return in FY21. This was due to unrealised losses associated with the significant increase in bond yields.
However, the insurer’s customers see the need for its service more than ever and were willing to pay more for an additional layer of protection.
The company recorded gross written premium growth of 13% and a groupwide renewal increase of 7.9%.
Looking to FY23, the company promised gross written premium growth of mid to high single digits.
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.

Blog Categories
Get Our Top 5 ASX Stocks for FY26
Recent Posts
Imricor Medical (ASX:IMR) FDA Approval Ignites Shares, but the Real Test Starts Now
FDA Approval Is a Big Win, Not the Finish Line Imricor Medical (ASX:IMR) received FDA clearance for its Vision-MR diagnostic…
How Nuclear Energy Became the World’s Most Feared Energy Source
Why Nuclear Energy Still Scares Us and What Really Went Wrong Many investors may remember periods when nuclear energy captured…
Dateline Resources (ASX:DTR) From 60c Highs to Hard Lessons
A Rare Earth Story the Market Loved Then Questioned For investors who have followed Dateline Resources (ASX:DTR), the past year…